Press Releases

All Releases
Nov 04, 2013
AngioDynamics to Present at Upcoming Investor Conferences
ALBANY, N.Y. , Nov. 4, 2013 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced today that Joseph M. DeVivo , President and Chief Executive Officer,
Oct 10, 2013
AngioDynamics Reports Fiscal 2014 First Quarter Financial Results
Net sales of $83.6 million GAAP net loss of $0.01 per share; Non-GAAP adjusted net income of $0.04 per share; Non-GAAP adjusted net income excluding amortization of $0.12 per share Adjusted EBITDA of $11.3 million Operating cash flow of $7.3 million versus prior year $5.6 million cash use Company
Sep 24, 2013
AngioDynamics Announces Debt Refinancing
ALBANY, N.Y. , Sept. 24, 2013 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced it amended its existing credit facilities and successfully
Sep 19, 2013
AngioDynamics to Report Fiscal 2014 First Quarter Financial Results
ALBANY, N.Y. , Sept. 19, 2013 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced it will report its fiscal 2014 first quarter financial results
Aug 01, 2013
AngioDynamics to Present at 33rd Annual Canaccord Growth Conference
ALBANY, N.Y. , Aug. 1, 2013 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, is scheduled to present at the 33 rd Annual Canaccord Growth Conference on
Jul 11, 2013
AngioDynamics Reports Fiscal 2013 Fourth Quarter Financial Results
Net sales of $90 million GAAP net loss of $0.02 per share; Adjusted (Non-GAAP) net income of $0.07 per share Adjusted EBITDA Grows 56% to $12.3 million Operating cash flow of $10.8 million versus $1 million of cash used in prior year Company Introduces Financial Guidance for FY 2014 ALBANY, N.Y.
Displaying 141 - 160 of 641